美国食品和药物管理局已批准第一种口服避孕药（OCP）作为非处方药。这种仅含孕激素的药丸含有每日服用 0.075 毫克的炔诺孕酮，珍珠指数估计为 4.4（95% CI，1.9-8.8）。该配方具有出色的安全性，目前乳腺癌是唯一的绝对禁忌症，相对禁忌症很少。最终，这一批准具有巨大的潜力，可以提高许多有怀孕能力的美国人，特别是那些难以获得医疗保健系统处方避孕药的人，特别是那些拥有边缘化身份的人，获得有效避孕的机会。该药在降低意外怀孕率方面的总体成功将取决于其可用性（特别是在可能依赖一家药房的农村社区）和负担能力（特别是对于没有保险或保险不足的个人）。然而，考虑到改进避孕药具供应的需要，特别是在限制堕胎的环境中，每日 OCP 的非处方批准是国家避孕生态系统的重大进步。版权所有 © 2023 美国妇产科学院。由 Wolters Kluwer Health, Inc. 出版。保留所有权利。

The U.S. Food and Drug Administration has approved the first oral contraceptive pill (OCP) for over-the-counter status. This progestin-only pill contains norgestrel 0.075 mg taken daily, with a Pearl Index estimated at 4.4 (95% CI, 1.9-8.8). This formulation has an excellent safety profile, with current breast cancer as the only absolute contraindication and few relative contraindications. Ultimately, this approval has great potential to improve the accessibility of effective contraception for many pregnancy-capable Americans, especially those who have poor access to the health care system for prescription-required contraception, most notably people who hold marginalized identities. The pill's overall success in reducing rates of unintended pregnancy will rely on its availability, particularly in rural communities that may rely on one pharmacy, and affordability, especially for uninsured or underinsured individuals. However, given the need for improved contraceptive provision, particularly in abortion-restrictive settings, the over-the-counter approval of this daily OCP is a major advancement in the nation's contraceptive ecosystem.Copyright © 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.